Get the Stockscreener App
9.66
0.00%
0.00
Pre-market:
9.09
-0.57
-5.90%
Aligos Therapeutics Inc stock is traded at $9.66, with a volume of 98,694.
It is up +0.00% in the last 24 hours and down -42.36% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$9.66
Open:
$9.39
24h Volume:
98,694
Relative Volume:
0.36
Market Cap:
$59.06M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.3978
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
-16.15%
1M Performance:
-42.36%
6M Performance:
+20.15%
1Y Performance:
-60.53%
1-Day Range:
$9.1377
$9.7378
1-Week Range:
$9.1377
$11.88
52-Week Range:
$6.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
9.66 | 59.06M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates - MSN
(ALGS) Long Term Investment Analysis - Stock Traders Daily
Aligos Therapeutics Presents Positive Data at APASL 2025 - The Manila Times
Clinical Trial Success: Aligos' Dual Breakthroughs in Liver Disease Show 100% Efficacy - StockTitan
Ten option delistings on March 24th - TipRanks
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and Compugen (NASDAQ:CGEN) - Armenian Reporter
Learn to Evaluate (ALGS) using the Charts - Stock Traders Daily
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Expands Team with Strategic Stock Option Package - StockTitan
HC Wainwright Issues Negative Outlook for ALGS Earnings - Defense World
Financial Comparison: Achilles Therapeutics (NASDAQ:ACHL) vs. Aligos Therapeutics (NASDAQ:ALGS) - Defense World
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy By Investing.com - Investing.com Australia
H.C. Wainwright cuts Aligos stock target to $70, maintains Buy - Investing.com India
Aligos Therapeutics (NASDAQ:ALGS) Price Target Lowered to $70.00 at HC Wainwright - Defense World
Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition - TipRanks
Aligos Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks
Aligos Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aligos Therapeutics reports fourth-quarter and full-year 2024 results -March 10, 2025 at 10:48 am EDT - Marketscreener.com
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last year - TipRanks
Aligos Therapeutics, Inc. SEC 10-K Report - TradingView
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Aligos Q4 Earnings: $105M Raise Backs Promising HBV Drug Results - StockTitan
Earnings Scheduled For March 10, 2025 - Benzinga
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday - Defense World
ALIGOS THERAPEUTICS Earnings Preview: Recent $ALGS Insider Trading, Hedge Fund Activity, and More - Nasdaq
How the (ALGS) price action is used to our Advantage - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 23.7% in February - Defense World
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025 - The Manila Times
Will Aligos Therapeutics Q4 Results Reveal Progress in Liver Disease Pipeline? - StockTitan
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Editas Medicine (NASDAQ:EDIT) - Defense World
(ALGS) Trading Report - Stock Traders Daily
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Decline in Short Interest - MarketBeat
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in January - Defense World
Aligos Therapeutics Announces $105 Million Private Placement FinancingAligos Therapeutics, Inc. (NASDAQ: ALGS) recently disclosed a Securities Purchase Agreement engagement entailing a Private Placement offering. The agreement includes the issuan - Defense World
Aligos Therapeutics, Inc. announced that it expects to receive $105.003206 million in funding - Marketscreener.com
Aligos Therapeutics secures $105 million in private placement By Investing.com - Investing.com Canada
Aligos Therapeutics secures $105 million in private placement - MSN
Aligos Therapeutics Secures $105M in Private Placement - TipRanks
Aligos Therapeutics rises after $105 million private placement - TradingView
Aligos Therapeutics announces $105M private placement financing - TipRanks
Aligos Therapeutics Announces $105 Million Private Placement Financing - The Manila Times
Major Funding Alert: Aligos Lands $105M Investment for Game-Changing Hepatitis B Drug Development - StockTitan
Trading (ALGS) With Integrated Risk Controls - Stock Traders Daily
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely - Yahoo Canada Finance
Aligos Therapeutics patents new inhibitors of PD-1, PD-L1 or PD-1/PD-L1 interaction - BioWorld Online
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last? - Yahoo Finance
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Update - MarketBeat
Aligos Therapeutics Appoints Lesley Ann Calhoun as COO - TipRanks
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):